Clinical Outcomes of Secondary Prophylactic Granulocyte Colony-Stimulating Factors in Breast Cancer Patients at a Risk of Neutropenia with Doxorubicin and Cyclophosphamide-Based Chemotherapy

Jae Hee Choi 1,2, Min Jung Geum 3,4, Ji Eun Kang 5,6, Nam Gi Park 7, Yun Kyoung Oh 2 and Sandy Jeong Rhie 1,5,7,*

Abstract: Doxorubicin and cyclophosphamide (AC)-based chemotherapy has been a standard regimen for early-stage breast cancer (ESBC) with an intermediate risk (10–20%) of febrile neutropenia (FN). Secondary prophylaxis of granulocyte colony-stimulating factor (G-CSF) is considered in patients receiving AC-based chemotherapy; however, relevant studies are limited. Here, we retrospectively reviewed the electronic medical records of 320 patients who completed adjuvant AC-based chemotherapy from September 2016 to September 2020. Approximately 46.6% of the patients developed severe neutropenic events (SNE) during AC-based chemotherapy. Secondary prophylaxis of G-CSF reduced the risk of recurrent SNE (p < 0.01) and the relative dose intensity (RDI) < 85% (p = 0.03) in patients who had experienced SNE during AC-based chemotherapy. Age ≥ 65 years (p = 0.02) and alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 60 IU/L (p = 0.04) were significant risk factors for RDI < 85%. The incidences of FN, grade 4 neutropenia, unscheduled hospitalization, and interruption to the dosing regimen were reduced in patients administered secondary prophylaxis with G-CSF (before vs. after administration: FN, 19.4% vs. 4.6%; grade 4 neutropenia, 86.1% vs. 14.8%; unscheduled hospitalization, 75.9% vs. 11.1%; interruption to the dosing regimen, 18.5% vs. 8.3%). This study indicated the importance of active intervention of G-CSF use to prevent recurrent SNE and improve clinical outcomes in patients with breast cancer who receive AC-based chemotherapy.

Keywords: secondary prophylaxis; granulocyte colony-stimulating factor; breast cancer; neutropenia; adjuvant chemotherapy; doxorubicin; cyclophosphamide

1. Introduction

Adjuvant chemotherapy for patients with early-stage breast cancer (ESBC) reduces the risk of recurrence and mortality [1,2]. Doxorubicin-and-cyclophosphamide (AC)-based chemotherapy is the most accepted standard regimen for ESBC [3,4]. Febrile neutropenia (FN) and grade 4 neutropenia are serious hematologic adverse reactions to chemotherapy that contains myelotoxic agents. They increase the risk of rapid infection progress and may lead to death. The incidences of FN and grade 4 neutropenia in patients with AC-based chemotherapy range from 4.6–29.5% and 44.6–66.4%, respectively [5–8]. In many cases,
prompt administration of prophylactic antibiotics and hospitalization are required until absolute neutrophil count (ANC) recovery [9,10].

The American Society of Clinical Oncology (ASCO), the European Organization for Research and Treatment of Cancer (EORTC), and the National Comprehensive Cancer Network (NCCN) guidelines recommend using primary prophylactic granulocyte colony-stimulating factor (G-CSF) when the risk of FN is >20% for all planned cycles of treatment [11–13]. The prophylactic use of G-CSF contributes to successful remission from breast cancer by maintaining ≥ 85% of the planned relative dose intensity (RDI) of chemo-medications during chemotherapy [14–17]. Moreover, the ASCO, EORTC, and NCCN guidelines define AC-based chemotherapy as an intermediate-risk (10–20%) regimen regarding FN and recommend considering secondary prophylaxis with G-CSF [11–13].

Previously, some researchers sought to evaluate the effect of secondary prophylaxis of G-CSF on reducing recurrent FN and maintaining RDI in patients with breast cancer who were treated with AC-based chemotherapy; however, the number of patient cases was limited, which reduced the statistical power [15,17,18]. Since September 2016, the National Health Insurance (NHI) in Korea has reimbursed the use of secondary prophylactic G-CSF for patients with breast cancer receiving AC-based chemotherapy. Therefore, it has become an affordable and common practice to administer prophylactic G-CSF in patients who experienced neutropenia. This is expected to improve patient outcomes. However, there are insufficient data to assess the impact of secondary prophylactic use of G-CSF in Korean patients with breast cancer.

We investigated the effects of secondary prophylactic administration of G-CSF and the risk factors of the recurrent FN, grade 4 neutropenia, and RDI < 85% in Korean patients with breast cancer who received AC-based chemotherapy.

2. Results
2.1. Patient Characteristics

There were 341 patients with breast cancer who completed adjuvant AC-based chemotherapy from September 2016 to September 2020. Twenty-one patients were excluded from the study because six were administered primary prophylactic G-CSF, nine had previous chemotherapy, four had hepatic or renal dysfunction, and two had missing values in laboratory tests. Thus, 320 patients were included and analyzed in this study. All patients were female, and the median age was 50 years. Most patients (86.9%) were in cancer stage I or II. One hundred and eight patients (33.8%) received the secondary prophylactic G-CSF of lipegfilgrastim (n = 63) or pegfilgrastim (n = 45). Another 65 patients (20.3%) received the G-CSF treatment of filgrastim, and the final 147 patients (45.9%) did not receive any G-CSF (Table 1).

Table 1. Patient characteristics (n, %) (N = 320).

| Characteristics                        | Number (%) |
|----------------------------------------|------------|
| Age (years), median (IQR)              | 50 (45–58) |
| Body mass index (kg/m²), median (IQR)  | 23.8 (21.7–26.2) |
| Body surface area (m²), median (IQR)   | 1.6 (1.5–1.7) |
| ER status                              |            |
| Negative                               | 58 (18.1%) |
| Positive                               | 262 (81.9%) |
| PR status                              |            |
| Negative                               | 149 (46.6%) |
| Positive                               | 171 (53.4%) |
| HER2 status                            |            |
| Negative                               | 275 (85.9%) |
| Positive                               | 45 (14.1%) |
Table 1. Cont.

| Characteristics          | Number (%) |
|--------------------------|------------|
| Cancer stage             |            |
| I                        | 97 (30.3%) |
| II                       | 181 (56.6%)|
| III                      | 42 (13.1%) |
| Comorbidities            |            |
| Cardiovascular diseases  | 54 (16.9%) |
| Diabetes mellitus        | 25 (7.8%)  |
| Thyroid diseases         | 20 (6.3%)  |
| Rheumatoid diseases      | 3 (0.9%)   |
| Menopause status         |            |
| Pre-menopause            | 177 (55.3%)|
| Post-menopause           | 143 (44.7%)|
| Use of G-CSF             |            |
| Secondary prophylaxis    | 108 (33.8%)|
| Lipegfilgrastim          | 63 (58.3%) |
| Pegfilgrastim            | 45 (41.7%) |
| Treatment                | 65 (20.3%) |
| None                     | 147 (45.9%)|
| Basal laboratory values, median (IQR) |          |
| WBC count ($\times 10^3/\mu L$) | 6.2 (5.2–7.2) |
| ANC (cells/mm$^3$)       | 3270 (2530–4130) |
| Hemoglobin (g/dL)        | 13.1 (12.3–13.7) |
| Platelet count ($\times 10^3/\mu L$) | 249.0 (218.3–295.0) |
| AST (IU/L)               | 24.0 (20.0–28.0) |
| ALT (IU/L)               | 17.0 (13.0–24.8) |

ANC, absolute neutrophil count; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ER, estrogen receptor; G-CSF, granulocyte colony-stimulating factor; HER2, human epidermal growth factor receptor 2; IQR, interquartile range; PR, progesterone receptor; WBC, white blood cell.

2.2. The Overall Incidence of Severe Neutropenic Events and Risk Factors

Almost half of the patients (149/320, 46.6%) developed SNE due to AC-based chemotherapy (FN: 9.4%, n = 30; grade 4 neutropenia: 42.8%, n = 137; both: 5.6%, n = 18). However, 12 patients were excluded because they developed FN or grade 4 neutropenia during the last chemotherapy cycle. Thus, 108 of the 137 patients were confirmed to have received secondary prophylactic G-CSF due to AC-based chemotherapy.

Multivariable analysis revealed that cancer stage III and diabetes mellitus (DM) were significant risk factors of FN (cancer stage III: odds ratio (OR) 4.20, 95% confidence interval (CI) 1.75–10.06; DM: OR 3.61, 95% CI 1.24–10.44). In grade 4 neutropenia, cancer stage III and basal Hb < 12 g/dL were significant risk factors (cancer stage III: OR 8.90, 95% CI 3.74–21.07; basal Hb < 12 g/dL: OR 2.23, 95% CI 1.14–4.38). Moreover, when we performed multivariable analysis to evaluate the risk factors of SNE in total, cancer stage III and basal Hb < 12 g/dL were significant risk factors of SNE (cancer stage III: OR 13.96, 95% CI 4.82–40.46; basal Hb < 12 g/dL: OR 2.41, 95% CI 1.21–4.78) (Table 2).

2.3. Recurrence of Severe Neutropenic Events and Its Risk Factors

The recurrence of SNE was 27.0% (n = 37/137) (FN: 5.1%, n = 7; grade 4 neutropenia: 24.1%, n = 33, both: 2.2%, n = 3) (Figure 1). Secondary prophylaxis of G-CSF was associated with reducing the risk of recurrent SNE (OR 0.17, 95% CI 0.07–0.43) (Table 3).
Table 2. Risk factors for febrile neutropenia, grade 4 neutropenia, and severe neutropenic events.

| Category                        | Univariable Analysis | Multivariable Analysis |
|---------------------------------|----------------------|------------------------|
|                                 | Variables            | Odds Ratio (95% CI)     | p-Value | Odds Ratio (95% CI)     | p-Value |
| FN (N = 320)                    | BSA ≥ 1.65 (vs. <1.65)| 0.55 (0.23–1.33)       | 0.19    | 0.45 (0.18–1.14)       | 0.09    |
|                                 | Cancer stage: III over I–II | 4.03 (1.73–9.37)   | <0.01   | 4.20 (1.75–10.06)      | <0.01   |
|                                 | DM present over absent | 3.57 (1.30–9.77)     | 0.01    | 3.61 (1.24–10.44)      | 0.02    |
| Grade 4 Neutropenia (N = 320)   | ER: positive over negative | 1.53 (0.85–2.78)     | 0.16    | 1.78 (0.92–3.44)       | 0.09    |
|                                 | Cancer stage: III over I–II | 8.63 (3.70–20.13)  | <0.01   | 8.90 (3.74–21.07)      | <0.01   |
|                                 | Basal Hb < 12 g/dL     | 2.46 (1.30–4.65)     | 0.01    | 2.23 (1.14–4.38)       | 0.02    |
|                                 | Basal WBC count < 4000/µL | 3.72 (0.97–14.30)  | 0.06    | 2.98 (0.71–12.61)      | 0.14    |
| Severe Neutropenic Events (N = 320) | Cancer stage: III over I–II | 14.29 (4.96–41.17)  | <0.01   | 13.96 (4.82–40.46)     | <0.01   |
|                                 | Basal Hb < 12 g/dL     | 2.55 (1.33–4.87)     | <0.01   | 2.41 (1.21–4.78)       | 0.01    |
|                                 | Basal WBC count < 4000/µL | 3.18 (0.83–12.20)  | 0.09    | 2.51 (0.59–10.70)      | 0.21    |

BSA, body surface area; DM, diabetes mellitus; ER, estrogen receptor; FN: febrile neutropenia, Hb, hemoglobin; WBC, white blood cell.

Figure 1. Secondary prophylaxis of G-CSF and recurrent severe neutropenic events. AC, doxorubicin and cyclophosphamide; G-CSF, granulocyte colony-stimulating factor.
Table 3. Risk factors for recurrent severe neutropenic events.

| Variables                                     | Univariable Analysis | Multivariable Analysis |
|-----------------------------------------------|----------------------|------------------------|
|                                               | Odds Ratio (95% CI)  | p-Value                |
|                                               |                      |                        |
| Age ≥ 65 years (vs. <65)                      | 0.67 (0.07–6.17)     | 0.72                   |
| BMI ≥ 25 (vs. <25)                            | 1.61 (0.75–3.46)     | 0.22                   |
| BSA ≥ 1.65 (vs. <1.65)                        | 0.85 (0.38–1.90)     | 0.70                   |
| ER: positive over negative                    | 0.82 (0.31–2.18)     | 0.69                   |
| PR: positive over negative                    | 1.40 (0.65–3.03)     | 0.39                   |
| HER2: positive over negative                  | 1.22 (0.46–3.27)     | 0.69                   |
| Cancer stage: III over I–II                   | 1.20 (0.52–2.77)     | 0.66                   |
| CV diseases present over absent               | 2.10 (0.84–5.21)     | 0.11                   |
| DM present over absent                        | 0.79 (0.21–3.06)     | 0.74                   |
| Post-menopause over pre-menopause             | 1.69 (0.79–3.62)     | 0.17                   |
| Basal Hb < 12 g/dL                            | 0.78 (0.30–2.01)     | 0.61                   |
| Basal WBC count < 4000/µL                     | 0.44 (0.05–3.74)     | 0.45                   |
| Basal ALT or AST > 40 IU/L                    | 0.69 (0.21–2.22)     | 0.53                   |
| Secondary prophylaxis of G-CSF                | 0.20 (0.08–0.47)     | <0.01                  |
|                                               | 1.58 (0.58–4.29)     | 0.37                   |

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BSA, body surface area; CV, cardiovascular; DM, diabetes mellitus; ER, estrogen receptor; G-CSF, granulocyte colony-stimulating factor; Hb, hemoglobin; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor; WBC, white blood cell.

2.4. RDI after Experiencing Severe Neutropenic Events

The mean RDI for patients who had SNE during overall chemotherapy was 94.1% in our study. RDI < 85% was present in 12.4% (17/137) of these patients. In multivariable analysis, age ≥ 65 years, ALT or AST > 60 IU/L elevation were the risk factors of RDI < 85% (age ≥ 65 years: OR 11.78, 95% CI 1.51–91.64; ALT or AST > 60 IU/L elevation: OR 3.51, 95% CI 1.09–11.37). Secondary prophylaxis of G-CSF reduced the risk of RDI < 85% (OR 0.27, 95% CI 0.08–0.86) (Table 4).

Table 4. Risk factors for RDI < 85% of patients with severe neutropenic events.

| Variables                                               | Univariable Analysis | Multivariable Analysis |
|---------------------------------------------------------|----------------------|------------------------|
|                                                         | Odds Ratio (95% CI)  | p-Value                |
|                                                         |                      |                        |
| Age ≥ 65 years (vs. <65)                                | 5.20 (0.80–33.68)    | 0.08                   |
| BMI ≥ 25 (vs. <25)                                      | 1.38 (0.50–3.83)     | 0.54                   |
| BSA ≥ 1.65 (vs. <1.65)                                  | 1.01 (0.35–2.93)     | 0.98                   |
| ER: positive over negative                              | 3.59 (0.45–28.54)    | 0.23                   |
| PR: positive over negative                              | 1.13 (0.40–3.17)     | 0.82                   |
| Cancer stage: III over I–II                             | 1.15 (0.37–3.51)     | 0.81                   |
| CV diseases present over absent                         | 2.08 (0.66–6.57)     | 0.21                   |
| DM present over absent                                  | 0.56 (0.07–4.62)     | 0.59                   |
| Thyroid diseases present over absent                    | 0.88 (0.10–7.47)     | 0.90                   |
| Post-menopause over pre-menopause                       | 1.47 (0.53–4.07)     | 0.46                   |
| Basal Hb < 12 g/dL                                      | 0.74 (0.20–2.76)     | 0.65                   |
| Basal WBC count < 4000/µL                               | 1.19 (0.13–10.51)    | 0.88                   |
| Basal ALT or AST > 40 IU/L                              | 3.15 (0.97–10.30)    | 0.06                   |
| ALT or AST > 60 IU/L elevation                          | 3.06 (1.08–8.70)     | 0.04                   |
| Recurrence of SNE                                       | 0.54 (0.15–2.01)     | 0.36                   |
| Secondary prophylaxis of G-CSF                          | 0.32 (0.11–0.94)     | 0.04                   |
|                                                         | 0.27 (0.08–0.86)     | 0.03                   |

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BSA, body surface area; CV, cardiovascular; DM, diabetes mellitus; ER, estrogen receptor; G-CSF, granulocyte colony-stimulating factor; Hb, hemoglobin; PR, progesterone receptor; SNE: severe neutropenic events; WBC, white blood cell.
2.5. Clinical Outcomes of Secondary Prophylaxis of G-CSF

The incidence of FN was reduced significantly after the administration of G-CSF (before G-CSF: 19.4%, n = 21; after G-CSF: 4.6%, n = 5, \( p < 0.01 \)). Moreover, the incidence of grade 4 neutropenia significantly decreased after the administration of G-CSF (before G-CSF: 86.1%, n = 93; after G-CSF: 14.8%, n = 16, \( p < 0.01 \)).

Unscheduled hospitalization due to SNE in the patients receiving secondary prophylactic G-CSF was 75.9% (n = 82) before administration. This decreased significantly to 11.1% (n = 12) after administration (\( p < 0.01 \)). Interruption to the dosing regimen due to SNE also decreased significantly, from 18.5% (n = 20) before administration to 8.3% (n = 9) after administration (\( p < 0.01 \)) (Figure 2).

![Clinical outcomes of secondary prophylaxis of G-CSF](image)

Figure 2. Clinical outcomes of secondary prophylaxis of G-CSF. FN: febrile neutropenia; G-CSF: granulocyte colony-stimulating factor. * \( p < 0.01 \).

3. Discussion

In this study, we confirmed that the use of secondary prophylaxis of second-generation G-CSF was associated positively with clinical outcomes. We found a decrease in recurrent SNE, unscheduled hospitalization, and interruptions to the chemotherapy regimen in Korean patients with ESBC who received adjuvant AC-based chemotherapy. Over the past decades, adjuvant anthracycline-based chemotherapy has been effective and safe in treating patients with breast cancer [3,4]. AC-based regimens (such as doxorubicin, 60 mg/m², and cyclophosphamide, 600 mg/m² every 3 weeks), alone or followed by docetaxel, are associated with great risk reduction, such as low myelosuppression. Therefore, they remain the choice adjuvant chemotherapy in patients with EBSC who have any level of risk [3,4,19,20]. Guidelines by the ASCO, EORTC, and NCCN recommend that a secondary prophylaxis of G-CSF should be considered in patients who have experienced FN and dose-limiting neutropenic events in intermediate-risk-group chemotherapy [11–13]. However, studies that have focused on its effect in patients with AC-based chemotherapy in clinical practice are limited. Previous studies have analyzed the effects of secondary prophylaxis of G-CSF on preventing dose reduction in patients with breast cancer treated using different adjuvant chemotherapies [15,17]. They have shown that this treatment regimen can delay the time...
until recurrent neutropenic events in different solid cancers, such as breast, colorectal, lung, and ovarian cancers [18].

Hepatic and renal dysfunction are risk factors of FN [5,21,22]. Only four patients in this study had hepatic and renal impairments at baseline. We excluded these from our analysis because they were not eligible for the full dose of chemotherapy, or because their chemo-schedule was postponed based on the protocol in our institution.

Cancer stage III, DM, and basal Hb < 12 g/dL were risk factors for FN and grade 4 neutropenia in this study. In line with this, advanced cancer stage has been reported as a risk factor for FN in two prediction model studies which included patients with breast cancer [23,24], as well as in a case series study with patients with non-Hodgkin’s lymphoma who received initial CHOP chemotherapy [25]. Supporting evidence to explain this association remains weak. The prediction model study suspected that advanced cancer stage and disease severity might reflect the rapid and early initiation of chemotherapy [23]. Unfortunately, most of our population started chemotherapy approximately four weeks after surgery; thus, this may not apply to our study. DM is associated with an increased risk of chemotherapy-induced neutropenia [26]. Uncontrolled DM, which may lead to unhealed wounds and poorly resolved infections, can increase one’s risk of FN and its complications [27]. Furthermore, we found a higher rate of unscheduled hospitalization due to SNE in patients with DM than in those without DM.

Basal Hb < 12 g/dL was a significant risk factor for grade 4 neutropenia in our study. A previous study has reported that pre-existing anemia may increase the risk of developing FN or severe neutropenia in patients treated with chemotherapy [28]. Lower levels of hemoglobin are associated with myelosuppression, which can further exacerbate the condition and lead to a higher incidence of FN [29]. This may explain why basal Hb < 12 g/dL increases the incidence of grade 4 neutropenia.

The administration rate of secondary prophylaxis of G-CSF was 78.8% (108/137) in our study, which was higher than the 66.7% (14/21) of Japanese patients with breast cancer who received an epirubicin and cyclophosphamide (EC) regimen from 2014 to 2018 [14]. This can be explained by the introduction of reimbursement for secondary prophylaxis G-CSF treatment by the Korea National Health Insurance (NHI) since September 2016. This treatment is not reimbursed in Japan. The recurrent SNE in the non-administered group of secondary prophylactic G-CSF was higher than in the administered group. This suggests that the secondary prophylaxis of G-CSF can protect against recurrent SNE. Additionally, after secondary prophylaxis of G-CSF, interruptions in the dosing regimen caused by SNE were significantly reduced. Secondary prophylaxis of G-CSF was effective in maintaining an adequate RDI, which reduced the recurrence of neutropenic events. This is consistent with the results of previous studies [15,17]. In this study, the mean RDI of patients with SNE was 94.1%; RDI < 85% was present in 12.4% (17/137) of these patients. The risk factors for RDI < 85% were age ≥ 65 years and elevated ALT or AST > 60 IU/L.

The risk of chemo-related adverse drug reactions increases as major organ function deteriorates in the elderly [30]; therefore, old age is a risk factor for RDI < 85% [4,31]. In our study, patients aged 65 years or older received a 10–25% dosing reduction during chemotherapy and were hospitalized for an average of 9.5 days due to chemotherapy-related adverse reactions, which was longer than the average of 4.0 days for younger patients. Doxorubicin and cyclophosphamide are metabolized in the liver; therefore, dose adjustments are required in hepatic dysfunction [32,33]. These properties of anticancer drugs have been shown in prospective studies that include patients with breast cancer; therefore, grade 2 and higher ALT or AST levels are defined as hepatic dysfunction [18,34]. In these cases, chemotherapy cycles are suspended until blood chemistry abnormalities are resolved to normal or grade 1. The most frequent cause of chemotherapy delay is transaminase elevation [34]. To the best of our knowledge, an association between transaminase elevation and risk of RDI < 85% has seldom been reported. It is reasonable to suggest close monitoring of sudden changes and upward trending of transaminase,
especially for ALT or AST > 60 IU/L, prior to chemotherapy. This would promote the administration of a full dose of chemotherapy without any reductions or delays.

This is a retrospective study using medical records from a single institution. We found that cancer stage III was a significant risk factor for FN; however, it was difficult to identify a pathological mechanism because our study only investigated medical records. Thus, further ex vivo studies will be required to elucidate the underlying mechanisms. We analyzed the risk factors for recurrence of SNE, but not FN and grade 4 neutropenia. Our study was conducted by collecting the medical records of 320 patients, which was not a small scale compared with previous studies; however, it was difficult to analyze the risk factors for each SNE. Therefore, larger studies will be required to analyze the risk factors of both recurrent FN and grade 4 neutropenia.

Despite these limitations, this study confirmed the most recent clinical practice trends from 2016 to 2020. Moreover, a similar study including patients who were being treated with different chemotherapies for several solid cancers reported a positive effect of secondary prophylaxis of G-CSF on decreased neutropenic events [18]. This is too generalized to apply these results to patients who received AC-based chemotherapy for breast cancer. Nonetheless, we conducted this study to evaluate the clinical outcomes of secondary prophylaxis of G-CSF in a sufficient number of patients with breast cancer who were treated with AC-based chemotherapy. Taken together, we found that secondary prophylaxis of G-CSF improved clinical outcomes; patients showed decreased rates of recurrent SNE, unexpected hospitalizations, and interruptions to the chemo-regimen.

4. Materials and Methods

4.1. Patients

We retrospectively reviewed the electronic medical records (EMR) of patients with breast cancer who were ≥18 years and had completed a course of AC-based chemotherapy as the adjuvant therapy from September 2016 to September 2020 at the Konkuk University Medical Center. Patients were excluded if they received primary prophylactic G-CSF, started AC-based chemotherapy at other hospitals, had received previous chemotherapy, had hepatic or renal dysfunction at baseline, or had missing values in laboratory tests.

Adjuvant AC-based chemotherapy in the routine clinical practice included AC and AC-D regimens. In general, patients on the AC regimen received doxorubicin at 60 mg/m² intravenously on day 1 and cyclophosphamide at 600 mg/m² intravenously on day 1 over 3 weeks for 4 cycles. On the AC-D regimen, patients received doxorubicin at 60 mg/m² intravenously on day 1 and cyclophosphamide at 600 mg/m² intravenously on day 1 over 3 weeks for 4 cycles followed by docetaxel at 75 mg/m² on day 1 over 3 weeks for 4 cycles. Secondary prophylaxis of G-CSF was defined as the administration of G-CSF to a patient who had experienced FN or grade 4 neutropenia to reduce their risk of neutropenia from subsequent chemotherapy. For secondary prophylaxis, lipegfilgrastim or pegfilgrastim was administered subcutaneously at a fixed dose of 6 mg once at 24 h after completion of each chemotherapy cycle.

4.2. Study Design

We collected the following patient information: age, sex, height, weight, body mass index (BMI), body surface area (BSA), estrogen receptor (ER) status, progesterone receptor (PR) status, human epidermal growth factor receptor 2 (HER2) status, cancer stage, comorbidities (cardiovascular diseases, diabetes mellitus, thyroid diseases, and rheumatoid diseases), menopause status, use of G-CSF, type of G-CSF, and laboratory values.

The incidence and risk factors of SNE after AC-based chemotherapy were analyzed. SNE referred to both FN and grade 4 neutropenia in this study. FN was defined as when patients had a single temperature > 38.3 °C or ≥38 °C for over 1 h and an ANC < 1000 cell/mm³. Grade 4 neutropenia was defined as an ANC < 500 cells/mm³, as previously reported in the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, or via diagnosis at the EMR by a physician in this study.
Additionally, the incidence and risk factors of recurrent SNE were assessed. RDI after experiencing SNE and the risk factors for low RDI (<85%) were assessed. Clinical outcomes were the occurrence of FN, grade 4 neutropenia, unscheduled hospitalization, and the interruptions to the dosing regimen (by dose reduction or dosing delay) of chemotherapy due to SNE.

4.3. Statistical Analysis

Categorical data were compared using the chi-squared or Fisher’s exact tests. McNemar’s test was used to compare the incidence of FN, grade 4 neutropenia, unscheduled hospitalization, and interruption to the dosing regimen of chemotherapy before and after administration of secondary prophylactic G-CSF. Logistic regression analysis was used to identify risk factors for FN, grade 4 neutropenia, and relative dose intensity (RDI) < 85%. RDI (%) was calculated with the equation: [actual total dose per week (mg/m²/week)]/[standard planned total dose per week (mg/m²/week)] [14]. Variables with \( p < 0.20 \) in the univariable analysis were entered into the multivariable logistic analysis. All statistical analyses were conducted using IBM SPSS® Statistics 28.0, and \( p < 0.05 \) was considered statistically significant.

5. Conclusions

Approximately 46.6% of patients experienced SNE during AC-based chemotherapy. Secondary prophylaxis of G-CSF reduced the recurrence of SNE and maintained RDI ≥ 85%. Further, it reduced the number of unscheduled hospitalizations and interruptions to the dosing regimen in patients on AC-based chemotherapy for breast cancer.

Author Contributions: Conceptualization: J.H.C. and S.J.R.; data curation: J.H.C.; formal analysis: J.H.C.; funding acquisition: S.J.R.; investigation and methodology: J.H.C. and M.J.G.; project administration: J.H.C. and S.J.R.; resources and software: J.H.C.; supervision: J.H.C., M.J.G. and N.G.P.; visualization: J.H.C.; writing and review of the manuscript: J.H.C., M.J.G., J.E.K., N.G.P., Y.K.O. and S.J.R. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean Government Ministry of Science and ICT (2020R1A2C1009224). This research was also supported by a grant from the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2017R1D1A1B03033889).

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of Konkuk University Medical Center (No. 2021-09-035).

Informed Consent Statement: Patient consent was waived as this was a retrospective study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author. The data are not publicly available due to privacy restrictions and patient confidentiality. This study used and rearranged part of the data for J.H.C.’s 2021 Ph.D. thesis.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Berry, D.A.; Cronin, K.A.; Feuer, E.J.; Plevritis, S.K.; Fryback, D.G.; Clarke, L.; Zelen, M.; Mandelblatt, J.S.; Yakovlev, A.Y.; Habbema, J.D.F. Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer. N. Engl. J. Med. 2005, 353, 1784–1792. [CrossRef] [PubMed]
2. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of Chemotherapy and Hormonal Therapy for Early Breast Cancer on Recurrence and 15-Year Survival: An Overview of the Randomised Trials. Lancet 2005, 365, 1687–1717. [CrossRef]
3. Fujii, T.; Le Du, F.; Xiao, L.; Kogawa, T.; Barcenas, C.H.; Alvarez, R.H.; Valero, V.; Shen, Y.; Ueno, N.T. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-Analysis. JAMA Oncol. 2015, 1, 1311–1318. [CrossRef] [PubMed]
4. Lyman, G.H.; Dale, D.C.; Crawford, J. Incidence and Predictors of Low Dose-Intensity in Adjuvant Breast Cancer Chemotherapy: A Nationwide Study of Community Practices. J. Clin. Oncol. 2003, 21, 4524–4531. [CrossRef] [PubMed]
5. Kim, H.S.; Lee, S.Y.; Kim, J.W.; Choi, Y.J.; Seo, J.H.; Shin, S.W.; Kim, Y.H.; Kim, J.S.; Park, K.H.; Park, I.H.; et al. Incidence and Predictors of Febrile Neutropenia among Early-Stage Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy in Korea. *Oncology* 2016, 91, 274–282. [CrossRef]

6. Kim, C.G.; Sohn, J.; Chon, H.; Kim, J.H.; Heo, S.J.; Cho, H.; Kim, I.J.; Kim, G.M.; Kim, S.I.; Park, S.; et al. Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy. *J. Breast Cancer* 2016, 19, 76–82. [CrossRef]

7. Von Minckwitz, G.; Raab, G.; Caputo, A.; Schütte, M.; Hilfrich, J.; Blohm, J.U.; Gerber, B.; Costa, S.D.; Merkle, E.; Eidtmann, H.; et al. Doxorubicin with Cyclophosphamide Followed by Docetaxel Every 21 Days Compared with Doxorubicin and Docetaxel Every 14 Days as Preoperative Treatment in Operable Breast Cancer: The GEOPARDUO Study of the German Breast Group. *J. Clin. Oncol.* 2005, 23, 2676–2685. [CrossRef]

8. Chan, A.; Chen, C.; Chiang, J.; Tan, S.H.; Ng, R. Incidence of Febrile Neutropenia among Early-Stage Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy. *Support Care Cancer* 2012, 20, 1525–1532. [CrossRef] [PubMed]

9. Pathak, R.; Aryan, M.R.; Karmacharya, P.; Giri, S.; Martin, M.G.; Bhatt, V.R. Mortality, Length of Stay, and Health Care Costs of Febrile Neutropenia-Related Hospitalizations among Patients with Breast Cancer in the United States. *Support Care Cancer* 2015, 23, 615–617. [CrossRef] [PubMed]

10. Lynn, J.; Chen, K.; Weng, Y.; Chiu, T. Risk Factors Associated with Complications in Patients with Chemotherapy-Induced Febrile Neutropenia in Emergency Department. *Hematol. Oncol.* 2013, 31, 189–196. [CrossRef]

11. Smith, T.J.; Bohlke, K.; Cross, S.J.; Khatcheressian, J.L.; Lyman, G.H.; Carson, K.R.; Crawford, J.; Goldberg, J.M.; Leighl, N.B.; Perkins, C.L.; et al. Recommendations for the use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. *J. Clin. Oncol.* 2015, 33, 3199–3212. [CrossRef] [PubMed]

12. Aapro, M.S.; Bohlhus, J.; Cameron, D.A.; Lago, L.D.; Donnelly, J.P.; Kearney, N.; Lyman, G.H.; Pettengell, R.; Tjän-Heijnen, V.; Walewski, J.; et al. 2010 Update of EORTC Guidelines for the use of Granulocyte-Colony Stimulating Factor to Reduce the Incidence of Chemotherapy-Induced Febrile Neutropenia in Adult Patients with Lymphoproliferative Disorders and Solid Tumours. *Eur. J. Cancer* 2011, 47, 8–32. [CrossRef]

13. Crawford, J.; Becker, P.S.; Armitage, J.O.; Blayney, D.W.; Chavez, J.; Curtin, P.; Dinner, S.; Fynan, T.; Gojo, I.; Griffiths, E.A.; et al. Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. *J. Natl. Compr. Cancer Netw.* 2017, 15, 1502–1541. [CrossRef]

14. Sakurada, T.; Bando, S.; Zamami, Y.; Goda, M.; Kirino, Y.; Nakamura, T.; Teraoka, K.; Ishizawa, K.; Takechi, K.; Chuma, M.; et al. Prophylactic Administration of Granulocyte Colony-Stimulating Factor in Epirubicin and Cyclophosphamide Chemotherapy for Japanese Breast Cancer Patients: A Retrospective Study. *Cancer Chemother. Pharmacol.* 2019, 84, 1107–1114. [CrossRef] [PubMed]

15. Leonard, R.C.F.; Mansi, J.L.; Keerie, C.; Yellowlees, A.; Crawford, S.; Benstead, K.; Matthew, R.; Adamson, D.; Chan, S.; Grieve, R. A Randomised Trial of Secondary Prophylaxis using Granulocyte Colony-Stimulating Factor (‘SPROG’ Trial) for Maintaining Dose Intensity of Standard Adjuvant Chemotherapy for Breast Cancer by the Anglo-Celtic Cooperative Group and NCRN. *Ann. Oncol.* 2015, 26, 2437–2441. [CrossRef] [PubMed]

16. Yokokawa, T.; Suzuki, K.; Sugisaki, T.; Kobayashi, K.; Shouji, D.; Watanabe, H.; Kawakami, K.; Takiguchi, T.; Aoyama, T.; Kobayashi, K. Impact of Primary Pegfilgrastim Prophylaxis on Relative Dose Intensity in Neoadjuvant/Adjuvant FEC-100 Chemotherapy. *Anticancer Res.* 2020, 40, 915–921. [CrossRef]

17. Chan, A.; McGregor, S.; Liang, W. Utilisation of Primary and Secondary G-CSF Prophylaxis Enables Maintenance of Optimal Dose Delivery of Standard Adjuvant Chemotherapy for Breast Cancer: An Analysis of 1655 Patients. *Breast J.* 2014, 20, 676–682. [CrossRef]

18. Freyer, G.; Jovenin, N.; Yazbek, G.; Villanueva, C.; Hussain, A.; Berthune, A.; Rotarski, M.; Simon, H.; Boulanger, V.; Hummelsberger, M.; et al. Granulocyte-Colony Stimulating Factor (G-CSF) has Significant Efficacy as Secondary Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Solid Tumors: Results of a Prospective Study. *Anticancer Res.* 2013, 33, 301–308. [PubMed]

19. Jones, S.; Holmes, F.A.; O'Shaughnessy, J.; Blum, J.L.; Vukelja, S.J.; McIntyre, K.J.; Pippen, J.E.; Bordelon, J.H.; Kirby, R.L.; Sandbach, J. Docetaxel and Cyclophosphamide is Associated with an overall Survival Benefit Compared with Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. *J. Clin. Oncol.* 2009, 27, 1177–1183. [CrossRef]

20. Waks, A.G.; Winer, E.P. Breast Cancer Treatment: A Review. *JAMA* 2019, 321, 288–300. [CrossRef]

21. Lyman, G.H.; Kuderer, N.M.; Crawford, J.; Wolff, D.A.; Culakova, E.; Poniewierski, M.S.; Dale, D.C. Predicting Individual Risk of Neutropenic Complications in Patients Receiving Cancer Chemotherapy. *Cancer* 2011, 117, 1917–1927. [CrossRef] [PubMed]

22. Lyman, G.H.; Abella, E.; Pettengell, R. Risk Factors for Febrile Neutropenia among Patients with Cancer Receiving Chemotherapy: A Systematic Review. *Crit. Rev. Oncol.* 2014, 90, 190–199. [CrossRef] [PubMed]

23. Hosmer, W.; Wong, M.; Malin, J. Development and Validation of a Prediction Model for the Risk of Developing Febrile Neutropenia in the First Cycle of Chemotherapy among Elderly Patients with Breast, Lung, Colorectal, and Prostate Cancer. *Support Care Cancer* 2011, 19, 333–341. [CrossRef] [PubMed]

24. Cho, B.J.; Kyoung, M.K.; Bilegasakhan, S.E.; Yong, J.S. Machine Learning Improves the Prediction of Febrile Neutropenia in Korean Inpatients Undergoing Chemotherapy for Breast Cancer. *Sci. Rep.* 2020, 10, 14803. [CrossRef] [PubMed]
25. Morrison, V.A.; Picozzi, V.; Scott, S.; Pohlman, B.; Dickman, E.; Lee, M.; Lawless, G.; Kerr, R.; Caggiano, V.; Delgado, D.; et al. The Impact of Age on Delivered Dose Intensity and Hospitalizations for Febrile Neutropenia in Patients with Intermediate-Grade Non-Hodgkin’s Lymphoma Receiving Initial CHOP Chemotherapy: A Risk Factor Analysis. Clin. Lymphoma 2001, 2, 47–56. [CrossRef]

26. Alenzi, E.O.; Kelley, G.A. The Association of Hyperglycemia and Diabetes Mellitus and the Risk of Chemotherapy-Induced Neutropenia among Cancer Patients: A Systematic Review with Meta-Analysis. J. Diabetes Complicat. 2017, 31, 267–272. [CrossRef] [PubMed]

27. Srokowski, T.P.; Fang, S.; Hortobagyi, G.N.; Giordano, S.H. Impact of Diabetes Mellitus on Complications and Outcomes of Adjuvant Chemotherapy in Older Patients with Breast Cancer. J. Clin. Oncol. 2009, 27, 2170–2176. [CrossRef] [PubMed]

28. Chao, C.; Page, J.H.; Yang, S.; Rodriguez, R.; Huynh, J.; Chia, V.M. History of Chronic Comorbidity and Risk of Chemotherapy-Induced Febrile Neutropenia in Cancer Patients Not Receiving G-CSF Prophylaxis. Ann. Oncol. 2014, 25, 1821–1829. [CrossRef] [PubMed]

29. Yokoyama, M.; Kusano, Y.; Nishihara, A.; Inoue, N.; Nishimura, N.; Mishima, Y.; Terui, Y.; Nukada, T.; Nomura, T.; Hatake, K. Incidence and Risk Factors for Febrile Neutropenia in Japanese Patients with Non-Hodgkin B Cell Lymphoma Receiving R-CHOP: 2-Year Experience in a Single Center (STOP FN in NHL 2). Support Care Cancer 2020, 28, 571–579. [CrossRef] [PubMed]

30. Davies, E.A.; O’Mahony, M.S. Adverse Drug Reactions in Special Populations—The Elderly. Br. J. Clin. Pharmacol. 2015, 80, 796–807. [CrossRef] [PubMed]

31. Shayne, M.; Culakova, E.; Lyman, G.H.; Crawford, J.; Dale, D.C. Predictors of Reduced Dose Intensity in Patients with Early-Stage Breast Cancer Receiving Adjuvant Chemotherapy. Breast Cancer Res. Treat. 2006, 100, 255–262. [CrossRef]

32. Damodar, G.; Smitha, T.; Gopinath, S.; Vijayakumar, S.; Rao, Y. An Evaluation of Hepatotoxicity in Breast Cancer Patients Receiving Injection Doxorubicin. Ann. Med. Health Sci. Res. 2014, 4, 74–79. [CrossRef] [PubMed]

33. Krens, S.D.; Lassche, G.; Jansman, F.G.A.; Desar, I.M.E.; Lankheet, N.A.G.; Burger, D.M.; van Herpen, C.M.L.; van Erp, N.P. Dose Recommendations for Anticancer Drugs in Patients with Renal or Hepatic Impairment. Lancet Oncol. 2019, 20, e200–e207. [CrossRef]

34. Wang, X.; He, Y.; Wang, T.; Xie, Y.; Li, J.; Ouyang, T.; Fan, Z. Efficacy of Pegfilgrastim to Support Neoadjuvant Dose-Dense Epirubicin and Cyclophosphamide Chemotherapy in Breast Cancer. Support Care Cancer 2019, 27, 3019–3025. [CrossRef] [PubMed]